Heron Therapeutics (HRTX) EBIAT (2016 - 2025)
Heron Therapeutics (HRTX) has disclosed EBIAT for 14 consecutive years, with -$3.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 180.64% year-over-year to -$3.0 million, compared with a TTM value of -$20.2 million through Dec 2025, down 48.71%, and an annual FY2025 reading of -$20.2 million, down 48.71% over the prior year.
- EBIAT was -$3.0 million for Q4 2025 at Heron Therapeutics, up from -$17.5 million in the prior quarter.
- Across five years, EBIAT topped out at $3.7 million in Q4 2024 and bottomed at -$63.9 million in Q1 2022.
- Average EBIAT over 5 years is -$27.4 million, with a median of -$22.4 million recorded in 2022.
- Peak annual rise in EBIAT hit 183.39% in 2025, while the deepest fall reached 260.87% in 2025.
- Year by year, EBIAT stood at -$54.6 million in 2021, then soared by 63.64% to -$19.9 million in 2022, then soared by 46.03% to -$10.7 million in 2023, then surged by 134.16% to $3.7 million in 2024, then plummeted by 180.64% to -$3.0 million in 2025.
- Business Quant data shows EBIAT for HRTX at -$3.0 million in Q4 2025, -$17.5 million in Q3 2025, and -$2.4 million in Q2 2025.